Inflammatory Bowel Disease(IBD)Database
This will be a comprehensive epidemiological, clinical, endoscopic and histological database for inflammatory bowel diseases patients in our medical center that will further provide clinical and basic investigations.
Inflammatory Bowel Disease
|Study Design:||Time Perspective: Prospective|
|Official Title:||Epidemiologic, Clinical, Endoscopic and Histological Database of Patients With Inflammatory Bowel Disease (IBD)|
- flactuations in gastrointestinal inflammation [ Time Frame: ongoing, up to 4 times a year ] [ Designated as safety issue: No ]
- development of IBD-related morbidity and complications over time [ Time Frame: ongoing, up to 4 times a year ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
blood serum, gastrointestinal biopsies, fecal samples
|Study Start Date:||January 2011|
|Estimated Study Completion Date:||December 2026|
|Estimated Primary Completion Date:||December 2026 (Final data collection date for primary outcome measure)|
Patients diagnosed with Inflammatory Bowel Disease (IBD)
patients after a Large Bowel Resection
Patients after a Large Bowel Resection, with or without a pouch.
Family members of IBD patients, Patients with Irritable Bowel Syndrome (IBS), Fap (familial polyposis)patients after a large bowel resection, Patient performing screening endoscopy
Inflammatory bowel diseases (IBD), which include Crohn's disease (CD), ulcerative colitis (UC), undefined IBD and pouchitis (in patients who required IPAA for their colitis) affects about two million people in the world. At this time there is no definitive cure and current treatment is aimed at managing the symptoms and inflammation that accompany these diseases. These diseases are predominantly chronic, and patients may experience various gastrointestinal symptoms depending on the location, nature, and extent of their disease. Both genetic and environmental factors play etiological roles. The overall goal of our research is to understand the etiology and course of these diseases in order to prevent and to manage cases more effectively. In order to do so we are aiming at building a comprehensive database that will include detailed clinical data conjoined with dedicated research information and collection of biological specimens that will target the gut epithelium immune system, the microbiota and specific genetic risk factors.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01266538
|Contact: Iris Dotan, MD PhDfirstname.lastname@example.org|
|Tel Aviv Sourasky Medical Center||Not yet recruiting|
|Tel Aviv, Israel, 64239|
|Sub-Investigator: Hagit Tulchinsky, MD|
|Sub-Investigator: Henit Yanai, MD|
|Principal Investigator:||Iris Dotan, MD PhD||Tel-Aviv Sourasky Medical Center|